Edition one of Phacilitate’s technology review series examines gene editing approaches by viral and non-viral methods and where to access these services. In partnership with Anemocyte
The manipulation of DNA and specific gene editing is one of the great scientific breakthroughs of our time. However, delivering gene modifying material into cells is a major bottleneck in the manufacturing of advanced therapies, particularly when it comes to the high volumes needed to meet the required doses.
This report focuses on the various methods of delivery, their relative advantages and disadvantages, as well as the companies that are offering them.
Read more to understand:
- Who’s offering non-viral approaches to cell engineering and how they are disrupting the cell membrane, including SQZ Biotech, Avectas and MaxCyte
- The key characteristics and qualities of the four main vector types
- A review of the organisations providing viral vectors for clinical and commercial needs